CARDIOLOGY / SYSTEMATIC REVIEW/META-ANALYSIS
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Due to various limitations of warfarin use, non-vitamin K oral anticoagulants have gradually become the first choice for the prevention of ischemic stroke. This article will comprehensively and systematically evaluate the efficacy and safety of apixaban and warfarin in the prevention of ischemic stroke, to provide an evidence-based reference for clinical diagnosis and treatment.

Material and methods:
A comprehensive search of electronic databases, including PubMed, Embase, Cochrane Library, Web of Science, Clinical Trials, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Database (CBM), and Wanfang Database, was performed, and the cut-off date for all databases was May 31, 2021. We reviewed a large number of studies on apixaban versus warfarin in the prevention of ischemic stroke. We compared the incidence of ischemic stroke, any other thromboembolic events, major bleeding, intracranial hemorrhage, and gastrointestinal hemorrhage.

Results:
From the initial search of 288 results, the final meta-analysis included 11 studies, comprising 6 retrospective cohort studies, 4 observational studies, and 1 randomized controlled trial, with a total of 240,652 patients. There was no statistically significant difference between apixaban and warfarin in incidence of ischemic stroke (OR = 0.80, 95% CI: (0.56, 1.16), p = 0.25) and thromboembolic events (OR = 0.83, 95% CI: (0.63, 1.10), p = 0.19). In the apixaban group, major bleeding (OR = 0.68, 95% CI (0.55, 0.84), p = 0.0003), intracranial hemorrhage (OR = 0.48, 95% CI (0.42, 0.56), p < 0.00001), and gastrointestinal hemorrhage (OR = 0.66, 95% CI (0.60, 0.72), p < 0.00001) were significantly lower than in the warfarin group.

Conclusions:
Apixaban has more advantages and a higher safety profile than warfarin, making it worthy of widespread use.
REFERENCES (25)
1.
Virani SAA, Aparicio H, Benjamin E, et al. 2021 Heart Disease and Stroke Statistics Update Fact Sheet At-a-Glance. J Am Heart Assoc 2021; 6: 5-7.
 
2.
Seeger J, Wohrle J. Apixaban: an update of the evidence for its place in the prevention of stroke in patients with atrial fibrillation. Core Evid 2020; 15: 1-6.
 
3.
Wańkowicz P, Nowacki P, Gołąb-Janowska M. Atrial fibrillation risk factors in patients with ischemic stroke. Arch Med Sci 2021; 17: 19-24.
 
4.
Wańkowicz P, Nowacki P, Gołąb-Janowska M. Risk factors for ischemic stroke in patients with non-valvular atrial fibrillation and therapeutic international normalized ratio range. Arch Med Sci 2019; 15: 1217-22.
 
5.
Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2017; 17: 238.
 
6.
Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 2019; 58: 1265-79.
 
7.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62.
 
8.
López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058.
 
9.
Lee SI, Sayers M, Lip GY, Lane DA. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Int J Clin Pract 2015; 69: 1341-8.
 
10.
Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 2017; 117: 1072-82.
 
11.
Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc 2018; 7: 8643.
 
12.
Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: 510.
 
13.
Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999; 20: 448-52.
 
14.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5.
 
15.
Christopher B, Granger MD, John H, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
 
16.
Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin 2016; 32: 2047-53.
 
17.
Gupta K, Trocio J, Keshishian A, et al. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naive non-valvular atrial fibrillation patients in the US Department of defense population. BMC Cardiovasc Disord 2019; 19: 142.
 
18.
Halvorsen S, Ghanima W, Hoxmark C, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 2017; 3: 28-36.
 
19.
Lamberts M, Staerk L, Olesen JB, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life danish patients. J Am Heart Assoc 2017; 6: 45-7.
 
20.
Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythm 2015; 31: 339-44.
 
21.
Staerk L, Fosbol EL, Lamberts M, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 2017; 38: 907-15.
 
22.
Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc 2017; 6: e005835.
 
23.
Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 2018; 49: 98-106.
 
24.
Whitehouse KR, Avula D, Kahlon T, et al. Apixaban: alternative anticoagulation for HeartMate 3 ventricular assist device. ASAIO J 2022; 68: 318-22.
 
25.
Imai N, Fujii Y, Amano M. Pharmacological properties and clinical efficacy of apixaban. Nihon Yakurigaku Zasshi 2013; 142: 247-54.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top